Overview
Neumora Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to brain diseases, with a pipeline targeting depression, schizophrenia, and other psychiatric disorders through novel receptor-targeted mechanisms. Their lead asset navacaprant is a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder.
More in Neuropharmaceuticals
Latest industry news
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health
2026-07-11 · Funding
BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus
2026-07-10 · Industry
FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach
2026-07-09 · Policy
Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans
2026-07-08 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
South San Francisco, USA
Funding
Public · NASDAQ: NRXS
Website
www.neumoratherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →